Genomic Health, Inc. (NASDAQ:GHDX) has received an average rating of “Hold” from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $56.43.
Several research firms have recently issued reports on GHDX. BidaskClub lowered shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Zacks Investment Research reissued a “hold” rating on shares of Genomic Health in a research report on Tuesday, November 13th. Canaccord Genuity reissued a “buy” rating and issued a $82.00 price objective (up previously from $70.00) on shares of Genomic Health in a research report on Wednesday, November 7th. CIBC began coverage on shares of Genomic Health in a research report on Wednesday, December 19th. They issued a “market perform” rating for the company. Finally, Needham & Company LLC began coverage on shares of Genomic Health in a research report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $86.00 price objective for the company.
In related news, CFO G Bradley Cole sold 8,576 shares of the firm’s stock in a transaction on Tuesday, November 13th. The shares were sold at an average price of $79.18, for a total transaction of $679,047.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 371,689 shares of the firm’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $71.75, for a total transaction of $26,668,685.75. The disclosure for this sale can be found here. Insiders sold 2,467,078 shares of company stock valued at $184,264,565 in the last three months. Company insiders own 45.80% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GHDX. Pacer Advisors Inc. acquired a new stake in Genomic Health during the 3rd quarter valued at $171,000. Quantamental Technologies LLC bought a new position in Genomic Health during the 4th quarter valued at $180,000. Trexquant Investment LP bought a new position in Genomic Health during the 3rd quarter valued at $202,000. WINTON GROUP Ltd bought a new position in Genomic Health during the 4th quarter valued at $213,000. Finally, D.A. Davidson & CO. bought a new position in Genomic Health during the 3rd quarter valued at $234,000. 90.10% of the stock is owned by institutional investors and hedge funds.
GHDX stock traded up $0.96 on Friday, hitting $78.69. 221,368 shares of the company were exchanged, compared to its average volume of 306,418. Genomic Health has a twelve month low of $30.04 and a twelve month high of $92.18. The firm has a market capitalization of $2.81 billion, a price-to-earnings ratio of 7,869.00 and a beta of 0.88.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.07 by $0.28. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The firm had revenue of $101.30 million during the quarter, compared to analyst estimates of $94.27 million. During the same quarter in the prior year, the business posted ($0.06) earnings per share. Genomic Health’s revenue for the quarter was up 23.2% compared to the same quarter last year. Sell-side analysts anticipate that Genomic Health will post 1.06 earnings per share for the current fiscal year.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Further Reading: Balance Sheet
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.